On 10 June 2016, the merger of Skyepharma PLC and Vectura Group plc completed and the combined group will be the Vectura Group.  Skyepharma’s website is no longer being updated. Please refer to www.vectura.com.

DISCLAIMER - issued by the Directors and Management of Skyepharma PLC (the "Company")

Research analysts have from time to time published material commenting on the Company. Any opinions, estimates or forecasts regarding the Company's performance made by such analysts are theirs alone and do not represent opinions, forecasts or predictions of the Company or its Management. By distributing the information below, the Company does not imply its endorsement of or concurrence with such information. The Company does not accept any responsibility whatsoever for the views of these or any other analysts.

The following analysts currently issue reports on the Company:


Dr Susie Jana

020 3077 5700


Max Herrmann

020 7710 7606

N+1 Singer

Sheena Berry

020 7496 3078

Rx Securities

Dr Samir Devani

020 7659 1263


Michal Cabadaj

020 7220 0554

N+1 Singer are brokers to the Company.

Investors may wish to contact any of the above analysts directly in order to obtain copies of the reports issued. Unless otherwise noted below, these cannot be obtained directly from Skyepharma and there is no obligation upon the analyst to provide any report. Any reports issued may have become out of date following publication and should be read accordingly.

Company research

Initiation of coverage – analyst interview
Skyepharma | 26/08/2015
An introductory interview as Michal Cabadaj commences coverage of Skyepharma plc and provides his view of the company

Finncap Video